Panel Overview:

Drawing on the wealth of experience from both sides of the presentation podium, our expert panelists will provide a 360-degree view of what makes a company presentation truly compelling. From crafting your narrative to leveraging the latest digital tools, this session will cover all aspects of a successful Biotech Showcase appearance.

Moderator:
Virginia Amann, Founder & CEO, ENTENTE

Speakers:
Annalee Armstrong, Senior Editor, BioSpace
Maria Ghazal, President & CEO, Healthcare Leadership Council (HLC)
Michael Heifetz, Managing Director, Alvarez & Marsal Public Sector Services

This hour-long conversation also introduces BioFuture 2025 Spotlight Panels, a new format designed to maximize exposure for participating companies, elevate visibility, and spark meaningful dialogue through expertly moderated discussions with real-time audience interaction. Instead of the traditional pitch presentation, Spotlight Panels create richer, more memorable experiences for audiences eager to discover and connect with the next wave of transformative biotech companies and technologies.

Join us October 13–15 in New York City for BioFuture, where therapeutic innovators, policymakers, and investors come together to assess and shape the future of healthcare. This year’s program will feature candid, unfiltered discussions on the convergence of rapidly evolving fields, including biopharma, digital medicine, big data, TechBio, AI, and more, as well as the impact of regulatory changes on the healthcare ecosystem. Register and learn more at BioFuture.com.

A new wave of biotech companies is bringing forward breakthrough technologies designed to target the most elusive proteins—opening the door to therapies once thought impossible. In this episode, we explore the science, innovation, and opportunities behind cracking the code of the so-called “undruggable” proteome.

Global thought leaders have set an ambitious goal: to develop a treatment that can slow the progression of Alzheimer’s by 2025. While late-stage clinical successes have been elusive over the past decade, scientific understanding of the disease has advanced dramatically, particularly in the areas of early diagnosis and disease progression. This episode explores the evolving science of Alzheimer’s, the surge in drug development targeting patients in the earliest stages, and the promise that earlier intervention could deliver better outcomes for patients.

We’ll explore how COVID has accelerated change across the system, and whether that disruption is ultimately driving positive transformation for patients, providers, and innovators.

In this episode, a panel of experts explores the latest research, the favorable regulatory environment, and the innovative business models fueling this electrifying wave of potential in bioelectrical therapeutics.

With the rise of virtual fundraising, European innovators are finding new opportunities to access ex-EU public and private capital. But is this trend sustainable? Where does non-dilutive funding fit? Is a NASDAQ listing the right path? And what other tools should CEOs and their teams be considering as they advance their assets? In this episode, industry leaders unpack these critical questions and explore the evolving landscape of European biopharma fundraising.

That’s why this session is essential for any CEO weighing Europe as a strategic option. While the challenges are real, the rewards of building a presence can be extraordinary—expanding patient access beyond the U.S. and significantly increasing market value. In this episode, senior biotech leaders share their current experiences and insights, covering critical decisions such as choosing a European HQ location, setting rollout timing and cadence, and, most importantly, avoiding the bear traps along the way.

In this episode, a panel of experts from Parexel Biotech, Health Advances, Johnson & Johnson Innovation, and others explore how biotech companies can plan their early development strategies to both attract investors and align with regulatory needs. Hear what investors are looking for and how biotechs can get ahead from the very start.

With value delivery at the forefront, this discussion examines how companies can measure and demonstrate value, the critical interplay between FDA and CMS on value propositions, and practical strategies for engaging payers.

This conversation explores strategies around clinical trial design, anticipating investor questions, and strengthening competitive positioning, all critical elements for shaping long-term success.

Hear firsthand insights from CEOs, business development executives, market access leaders, country managers, and royalty investors representing leading companies such as Alexion, DRI Capital, Genentech, Genzyme, GSK, and Pfizer.

Drawing on the wealth of experience from both sides of the presentation podium, our expert speakers will provide a 360-degree view of what makes a company presentation truly compelling. From crafting your narrative to leveraging the latest digital tools, this session will cover all aspects of a successful Biotech Showcase appearance.

This discussion will provide a comprehensive outlook on the biotech financial markets, offering valuable insights for investors, executives, and industry professionals. Listeneres will gain a deeper understanding of the key factors shaping the market and learn how to navigate effectively in 2025 and beyond.

We’ll discuss the latest clinical progress, what it could mean for extending both lifespan and health span, and the broader impact these innovations may have on healthcare and society as a whole.